Sunday, May 9, 2021  | 26 Ramadhan, 1442
Samaa TV
Facebook Twitter Youtube
HOME > Health

Mirza assures availability of medicines used in coronavirus treatment

Says authorities have been directed to arrest black marketeers

SAMAA | - Posted: Jun 13, 2020 | Last Updated: 11 months ago
SAMAA |
Posted: Jun 13, 2020 | Last Updated: 11 months ago
Mirza assures availability of medicines used in coronavirus treatment

PM's aide Dr Zafar Mirza. Photo: Samaa TV FILE

PM’s aide on health Dr Zafar Mirza has assured the availability of medicines used for the treatment of coronavirus patients, the Radio Pakistan reported Saturday.

The PM’s aide presided over a meeting on the coronavirus situation in Islamabad Saturday. He said Tocilizumab and Remedesivir injections used for treating COVID-19 patients were being made available by the government.

Mirza said these injections will be distributed to critically ill patients through a robust mechanism to meet the needs of various hospitals.

The government took immediate action over reports of short supply of these two injections, according to the PM’s aide. There was an improvement in availability of the Tocilizumab injection after extensive efforts.

Strict action will be taken against the ones involved in over-charging or black marketeering of life-saving drugs under the DRAP Act, he warned.

Mirza urged the masses to inform DRAP on its toll-free number 0800-03727 in case they were over-charged for Actemra injection.

He said directions had been issued to the National Task Force on Eradication of Spurious and Sub-standard Drugs to apprehend black marketeers and the ones charging more than the approved prices of these drugs.

The number of known coronavirus cases has jumped to 134,667 in Pakistan. The virus has so far killed 2,574 people in the country.

FaceBook WhatsApp
 
HOME  
 
 
RELATED STORIES

Tell us what you think:

Your email address will not be published.

FaceBook WhatsApp
 

 
 
Pakistan, coronavirus, Zafar Mirza, drugs, Tocilizumab and Remedesivir injections
 
 
 
 
 
 
About Us   |   Anchor Profiles   |   Online Advertising   |   Contact Us   |   Feedback   |   Apps   |   FAQs   |   Authors   |   Comment Policy
Facebook   |   Twitter   |   Instagram   |   YouTube   |   WhatsApp